Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Page 1
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.
Iudici M, Mongin D, Siegert E, Carreira PE, Distler J, Henes J, Zanatta E, Hachulla E, De Luca G, de Souza Müller C, Santiago T, Tandaipan JL, Valdetaro Bianchi B, De Santis M, Hoffmann-Vold AM, Gabrielli A, Distler O, Courvoisier DS; EUSTAR collaborators. Iudici M, et al. Rheumatology (Oxford). 2023 Apr 3;62(4):1559-1567. doi: 10.1093/rheumatology/keac533. Rheumatology (Oxford). 2023. PMID: 36099040
OBJECTIVES: To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries. ...GCs utilization varied within and across countries, and grad …
OBJECTIVES: To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and va …
Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection.
Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, Mengin A, Gras A, Vidailhet P, Arnould-Michel R, Bibi-Triki S, Carapito R, Trouillet-Assant S, Perret M, Belot A, Bahram S, Arnaud L, Gottenberg JE, Fafi-Kremer S, Sibilia J. Scherlinger M, et al. Among authors: sibilia j. Infect Dis Ther. 2021 Sep;10(3):1747-1763. doi: 10.1007/s40121-021-00484-w. Epub 2021 Jul 10. Infect Dis Ther. 2021. PMID: 34245450 Free PMC article.
Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases.
Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, Costecalde C, Pijnenburg L, Fort J, Chatelus E, Sordet C, Javier RM, Gottenberg JE, Sibilia J, Fuentes-Silva YJ, Arnaud L. Felten R, et al. Among authors: sibilia j. Rheumatology (Oxford). 2021 Oct 9;60(SI):SI68-SI76. doi: 10.1093/rheumatology/keab432. Rheumatology (Oxford). 2021. PMID: 33983432 Free PMC article.
However, patients from cluster #2 (hesitant) and #3 (suspicious) were significantly more concerned about vaccination, the use of a new vaccine technology, lack of long-term data in relation to COVID-19 vaccination, and potential financial links with pharmaceutical companie …
However, patients from cluster #2 (hesitant) and #3 (suspicious) were significantly more concerned about vaccination, the use of a new vacci …
Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.
Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, Dougados M, Fautrel B, Flipo RM, Goupille P, Mariette X, Saraux A, Schaeverbeke T, Sibilia J, Vittecoq O, Daurès JP. Combe B, et al. Among authors: sibilia j. Rheumatology (Oxford). 2021 Nov 3;60(11):5073-5079. doi: 10.1093/rheumatology/keab398. Rheumatology (Oxford). 2021. PMID: 33961011
Positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a robust predictor of long-term outcome. CONCLUSIONS: We report a very mild 10-year outcome of a large cohort of patients with early RA diagnosed in the early 2000s, which was much better than re …
Positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a robust predictor of long-term outcome. CONCLUSIONS: W …
Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).
Hamidou M, Néel A, Poupon J, Amoura Z, Ebbo M, Sibilia J, Viallard JF, Gaborit B, Volteau C, Hardouin JB, Hachulla E, Rieger F. Hamidou M, et al. Among authors: sibilia j. Arthritis Res Ther. 2021 Mar 3;23(1):70. doi: 10.1186/s13075-021-02454-6. Arthritis Res Ther. 2021. PMID: 33658052 Free PMC article. Clinical Trial.
The primary endpoint was the occurrence of adverse events (AEs) and secondary endpoints were the number of SLE Responder Index 4 (SRI-4) responders at week 24 and reduction of corticosteroid dosage. In an exploratory analysis, we collected long-term data for safety and att …
The primary endpoint was the occurrence of adverse events (AEs) and secondary endpoints were the number of SLE Responder Index 4 (SRI-4) res …
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
Allanore Y, Bozzi S, Terlinden A, Huscher D, Amand C, Soubrane C, Siegert E, Czirják L, Carreira PE, Hachulla E, Zanatta E, Li M, Airò P, Mendoza FA, Rosato E, Distler O; EUSTAR Collaborators. Allanore Y, et al. Arthritis Res Ther. 2020 Oct 28;22(1):257. doi: 10.1186/s13075-020-02329-2. Arthritis Res Ther. 2020. PMID: 33115544 Free PMC article.
HAQ-DI score, major advanced organ involvement, and death were successfully used to model long-term disease progression in dcSSc. CONCLUSIONS: HAQ-DI score and major advanced organ involvement were comparable predictors of mortality risk in dcSSc. ...
HAQ-DI score, major advanced organ involvement, and death were successfully used to model long-term disease progression in dcSSc. CON …
Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA).
Molto A, Gossec L, Poiraudeau S, Claudepierre P, Soubrier M, Fayet F, Wendling D, Gaudin P, Dernis E, Guis S, Pouplin S, Ruyssen-Witrand A, Chales G, Mariette X, Beauvais C, Combe B, Flipo RM, Richette P, Chary-Valckenaere I, Saraux A, Sibilia J, Schaeverbeke T, Dougados M. Molto A, et al. Among authors: sibilia j. Rheumatology (Oxford). 2021 Feb 1;60(2):888-895. doi: 10.1093/rheumatology/keaa480. Rheumatology (Oxford). 2021. PMID: 33063096 Clinical Trial.
Despite a lack of statistical significance in the primary outcome (e.g. coping) there was a statistically significant difference in favor of this program for the following variables: change in BASDAI, number and duration of the home exercises in the active group, and physical act …
Despite a lack of statistical significance in the primary outcome (e.g. coping) there was a statistically significant difference in favor of …
Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial.
Molto A, Gossec L, Poiraudeau S, Claudepierre P, Soubrier M, Fayet F, Wendling D, Gaudin P, Dernis E, Guis S, Pouplin S, Ruyssen A, Chales G, Mariette X, Beauvais C, Combe B, Flipo RM, Richette P, Chary-Valckenaere I, Saraux A, Sibilia J, Schaeverbeke T, Dougados M. Molto A, et al. Among authors: sibilia j. Semin Arthritis Rheum. 2020 Aug;50(4):701-708. doi: 10.1016/j.semarthrit.2020.05.012. Epub 2020 May 27. Semin Arthritis Rheum. 2020. PMID: 32521324 Clinical Trial.
However, the number of patients in agreement with recommendations was significantly higher in the active group for vaccinations (flu vaccination: 28.6% vs. 9.9%, p<0.01; pneumococcal vaccination:40.0% vs. 21.1%,p=0.04), for cancer screening (skin cancer screening: 36.3% vs. 17 …
However, the number of patients in agreement with recommendations was significantly higher in the active group for vaccinations (flu vaccina …
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puéchal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Among authors: sibilia j. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2. Ann Intern Med. 2020. PMID: 32479166 Clinical Trial.
The history of lupus throughout the ages.
Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. Felten R, et al. Among authors: sibilia j. J Am Acad Dermatol. 2022 Dec;87(6):1361-1369. doi: 10.1016/j.jaad.2020.04.150. Epub 2020 May 4. J Am Acad Dermatol. 2022. PMID: 32380218 Review.
The word lupus (Latin term for the wolf) was used indistinctively since the Middle Ages for several types of diseases characterized by ulcerous lesions, mainly in the lower limbs. In the middle of the 18th century, the French dermatologist Cazenave mentioned for the first …
The word lupus (Latin term for the wolf) was used indistinctively since the Middle Ages for several types of diseases characterized b …
42 results